Paper Details

  1. Home
  2. Paper Details

Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome.

Author: GaoFang, GatesSimon, LambSarah E, McCabeChris, PerkinsGavin D, YoungDuncan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This article describes the Beta Agonist Lung Injury TrIal (BALTI-2), a multicentre, pragmatic, randomised, double-blind, placebo-controlled clinical trial which aims to determine if sustained treatment with intravenous (IV) salbutamol will improve survival in acute respiratory distress syndrome (ARDS).
Paper Details　
Original Abstract of the Article :
The acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in critically ill patients. Experimental studies suggest that treatment with beta agonists may be helpful in ARDS. The Beta Agonist Lung Injury TrIal (BALTI-2) is a multicentre, pragmatic, randomised, double-blin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113985/

データ提供：米国国立医学図書館（NLM）

BALTI-2: A Trial Investigating Beta Agonists in ARDS

The acute respiratory distress syndrome (ARDS) is a serious and often life-threatening condition that affects the lungs. This study, known as the Beta Agonist Lung Injury Trial (BALTI-2), investigates the potential therapeutic benefits of beta agonists, a class of drugs commonly used to treat asthma, for patients with ARDS. This multicenter, randomized, double-blind, placebo-controlled clinical trial aims to determine if sustained treatment with intravenous salbutamol, a beta agonist, improves survival in patients with ARDS. The study's findings have the potential to significantly impact the clinical management of ARDS, a condition that poses a significant challenge to healthcare providers.

Exploring New Therapies: Beta Agonists in ARDS

The study explores the potential of beta agonists, a class of drugs that stimulate the respiratory system, as a treatment for ARDS. This trial represents a promising step in the search for new and effective therapies for this complex and life-threatening condition.

A Breath of Hope: New Treatments for ARDS

Imagine a desert landscape, where the air is thick with dust and the lungs struggle to breathe. This study, like a refreshing breeze, seeks to bring relief to those suffering from ARDS. By exploring the potential of beta agonists, researchers hope to discover new treatments that can improve the quality of life and survival rates for patients with this debilitating condition.

Dr.Camel's Conclusion

This research investigates the potential benefits of beta agonists, a class of drugs known for their role in asthma treatment, for patients with ARDS. The BALTI-2 trial offers a promising avenue for exploring new and effective therapies for this serious lung condition. The findings hold the potential to significantly impact the clinical management of ARDS, bringing hope to patients battling this challenging disease.

Date :
  1. Date Completed 2011-09-16
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21554679

DOI: Digital Object Identifier

PMC3113985

Related Literature

Article Analysis
・Side Effects of albuterol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.